ANTITUMOR EFFECTIVENESS OF THE COMBINED APPLICATION OF BACTERIA OF THE GENUS BIFIDOBACTERIUM AND B. SUBTILIS IMV B-7724 LECTIN


N.I. Fedosova, N.L. Cheremshenko, A.V. Chumak, V.G. Tikhonov, K.D. Tarnopolska, I.M. Voyeykova
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of NAS of Ukraine, Kyiv, Ukraine

DOI: https://doi.org/10.15407/oncology.2024.02.133

 

Summary. Aim: to investigate of the antitumor effectiveness of the combined use of bacteria of the genus Bifidobacterium and the extracellular metabolite (lectin) of B. subtilis IMV B-7724. Object and methods: studies were performed on Balb/c mice (n = 52). Ehrlich adenocarcinoma was used as an experimental model. Starting from the 2nd day after the transplantation of tumor cells, the animals of the experimental groups were injected with lectin B. subtilis IMV B-7724 (s/c, 1 mg/kg of body weight, No. 10), B. animalis (per os, 7×105 CFU/ mouse, No. 10) or used their combination. The frequency of transplantation (%), the latent period of tumor emergence, the volume of tumors (mm3), and the life expectancy of animals were evaluated. Statistical processing of the results was carried out according to generally accepted methods of variational statistics. Results: administration of B. subtilis IMB B-7724 lectin (both alone and in combination with B. animalis) to mice with Ehrlich adenocarcinoma resulted in a significant inhibition of tumor growth. The tumor growth inhibition index was 55.0 and 50.5%, respectively. the animals of these groups were also characterized by a statistically significant increase in life expectancy compared to the control group: by 61.4 and 50.0%, respectively. The use of B. animalis alone did not have such a pronounced effect. Conclusion: on the Ehrlich adenocarcinoma model, a pronounced antitumor effect (inhibition of primary tumor growth, increase in life expectancy), both with the combined use of B. animalis and B. subtilis IMV B-7724 lectin, and with the separate administration of the bacterial lectin was demonstrated. The use of B. animalis alone did not affect the dynamics of tumor growth and the life expectancy of animals.

 

References

  1. Noor A, Naveed AK, Jibran SM, Ruqaiyyah The role of gut microbiome in cancer genesis and cancer prevention. Health Sciences Review 2022; 2: 100010. https://doi.org/10.1016/j. hsr.2021.100010.
  2. Devi TB, Devadas K, George M, et al. Low Bifi  te­ rium abundance in the lower gut microbiota is associated with helicobacter pylori-related gastric ulcer and gastric canc Front Microbiol 2021; 12: 631140. doi: 10.3389/ fmicb.2021.631140.
  3. Chen H, Jiang X, Zhu F, et al. Characteristics of the oral and gastric microbiome in patients with early-stage intramucosal esophageal squamous cell carcino BMC Microbiol 2024; 24 (1): 88. doi: 10.1186/s12866-024-03233-4.
  4. Ma J, Li J, Jin C, et al. Association of gut microbiome and primary liver cancer: A two-sample Mendelian randomization and case-control study. Liver Int 2023; 43 (1): 221–33. doi: 11111/liv.15466.
  5. Tuominen H, Rautava Oral microbiota and cancer development. Pathobiology 2021; 88 (2): 116–26. doi: 10.1159/ 000510979.
  6. Shvets YuV, Lykhova OO, Chekhun VF. Human microbiota and breast Exp Oncol 2022; 44 (2): 95–106. doi: 10.32471/exp-oncology.2312-8852.vol-44-no-2.17855.
  7. Bernardo G, Le Noci V, Di Modica M, et al. The emerging role of the microbiota in breast cancer progression. Cells 2023; 12 (15): 1 doi: 10.3390/cells12151945.
  8. Shvets YuV, Lukianova NYu, Chekhun VF. Human microbiota and effectiveness of cancer chemotherapy. Exp Oncol 2020; 42 (2): 82–93. doi: 32471/exp-oncology.2312-8852.vol- 42-no-2.14611.
  1. Sharma D, Gajjar D, Seshadri Understanding the role of gut microfloral bifidobacterium in cancer and its potential therapeutic applications. Microbiome Research Reports 2024; 3 (1): 3. http://dx.doi.org/10.20517/mrr.2023.51.
  2. Pei B, Peng S, Huang C, et al. Bifi  terium modulation of tumor immunotherapy and its mechanism. Cancer Immunol Immunother 2024; 73: 94 https://doi.org/10.1007/s00262-024-03665-x.
  1. Procaccianti G, Roggiani S, Conti G, et al. Bifidobacterium in anticancer immunochemotherapy: friend or foe? Microbiome Res Rep 2023; 2 (3): doi: 10.20517/mrr.2023. 23.
  2. Ferdous UT, Shishir MA, Khan SN, Hoq Bacillus spp.: Attractive sources of anti-cancer and anti-proliferative biomolecules. Microbial Bioactives 2018; 1 (1): 033–045. doi:  10.25163/microbbioacts.11005B0408130818.
  3. Aimaier R, Li H, Cao W, et al. The secondary metabolites of bacillus subtilis strain z15 induce apoptosis in hepatocellular carcinoma Probiotics Antimicrob Proteins 2023. doi: 10.1007/s12602-023-10181-4.
  4. European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientifi Purposes ETS 123. Protection of Vertebrate Animals, 1III.1986.https://norecopa.no/media/2iydns5h/ets-123-original. pdf.
  5. Podgorsky The method for the obtainmen of bacterial lectin, specific to sialic acids. (Pat. № 1791 UA). Publ. 23.01.1991. (in Ukrainian).
  6. Stefanov OV. Doklinichni doslidzhennya likarskykh zaso- biv [Preclinical studies of drugs]. Kyiv: Avitsena; 2001 (in Ukrainian).
  7. Dolati M, Tafvizi F, Salehipour M, et al. Inhibitory eff of probiotic Bacillus coagulans against MCF7 breast cancer cells. Iran J Microbiol 2021; 13 (6): 839–47. doi: 10.18502/ ij      3i6.8089.
  8. Chumak A, Shcherbina V, Fedosova N, Chekhun V. Polarization of macrophages of mice under the infl ence of lectin from Bacillus Subtilis IMB B-7724 EUREKA: Life Sciences 2021; (3): 3–10. doi: 21303/2504-5695.2021.001878.
  9. Chumak AV, Fedosova NI, Cheremshenko NL, et al. The evaluation of antitumor properties of subtilis IMV B-7724 lectin in studies in vivo. Oncology 2022; 24 (1): 31–6. doi: 10.32471/oncology.2663-7928.t-24-1-2022-g.10306.
  10. Akbaba M, Gokmen GG, Kışla D, Nalbantsoy A. In vivo investigation of supportive immunotherapeutic combination of Bifidobacterium infantis 35624 and doxorubicin in murine breast cancer. Probiotics Antimicrob Proteins 2023; 15 (4): 880–8. doi:  1007/s12602-021-09899-w.
  11. Matson V, Chervin CS, Gajewski TF. Cancer and the micro- biome-infl ence of the commensal microbiota on cancer, immune responses, and Gastroenterology 2021; 160 (2): 600–13. doi: 10.1053/j.gastro.2020.11.041.
  12. Bo Pei, Shixuan Peng, Chuying Huang, Fuxiang Bifidobacterium modulation of tumor immunotherapy and its mechanism. Cancer Immunol Immunother 2024; 73: 94. https://doi.org/10.1007/s00262-024-03665-x.

No comments » Add comment